FATE — FATE THERAPEUTICS INC

—
Nasdaq · Health Care · Biotechnology · CIK 1434316 ·
Last close
$1.02
Market Cap
$124.00M
52W High
$3.23
52W Low
$0.95
ADV30
1,516,698
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -32,247,000 -30,687,000 238,275,000 43,942,000 105,243,000
Jun 2026 2,082,000 — -31,134,000 -30,159,000 260,103,000 32,429,000 106,665,000
Mar 2026 1,299,000 — -33,000,000 -31,213,000 284,916,000 39,570,000 105,209,000
Dec 2025 1,369,000 — -34,721,000 -32,374,000 318,937,000 46,628,000 111,753,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-101,944,000
Investing CF
$87,046,000
Financing CF
$5,490,000
CapEx
$-3,714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.05
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,595,681,000
Inventory
—
Receivables
$703,000
ST Investments
$121,341,000
EBIT TTM
$-133,590,000
Pretax Income TTM
$-125,996,000
Interest Exp TTM
—
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,491,000
EBITDA
$-120,502,000
Free Cash Flow
$-48,659,248
Enterprise Value
$143,575,952
Total Cash
$153,770,000
Total Debt
$75,675,000
Shares Out
121,568,755
Trailing EPS
$-1.03
Book Value
$1.80
ROE
-60.8%
ROA
-26.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 6,646,000 -147,704,000 -136,315,000 318,937,000 111,753,000 207,184,000 -106,084,000
Dec 2024 13,631,000 -195,539,000 -186,262,000 440,694,000 121,968,000 318,726,000 -122,874,000
Dec 2023 63,533,000 -190,511,000 -160,928,000 506,217,000 137,800,000 368,417,000 -132,263,000
Dec 2022 96,300,000 -308,386,000 -281,721,000 705,561,000 221,622,000 483,939,000 -248,208,000

TTM Snapshot

Revenues TTM
$6,491,000
NetIncome TTM
$-125,996,000
OpCashFlow TTM
—
Assets (Latest)
$260,103,000
Forward EPS
$-0.97

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.00 · spot: $1.05 · call volume: 1 · put volume: 600

Peers — same industry

TickerNameMarket CapLastDaily %
ENGN enGene Therapeutics Inc. $115.27M $1.72 —
CRDL Cardiol Therapeutics Inc. $113.53M $0.97 —
TARA Protara Therapeutics, Inc. $137.10M $2.32 —
HUMA Humacyte, Inc. $139.18M $0.50 —
LENZ LENZ Therapeutics, Inc. $109.97M $3.50 —

News headlines (Yahoo Finance, 1h cache)

Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy
2026-11-10 12:00 · Yahoo
Fate Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:16 · Yahoo
Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
2026-11-05 12:00 · Yahoo
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-11-03 21:05 · Yahoo
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
2026-10-26 11:00 · Yahoo
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
2026-10-12 11:00 · Yahoo
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
2026-10-01 11:00 · Yahoo
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
2026-09-25 11:00 · Yahoo
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
2026-09-03 11:00 · Yahoo
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 13:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.